AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 1,262,761 shares, an increase of 85.5% from the August 15th total of 680,697 shares. Based on an average daily trading volume, of 190,374 shares, the days-to-cover ratio is currently 6.6 days. Approximately 2.1% of the shares of the company are sold short.

A number of research firms have recently weighed in on AVEO. FBR & Co reaffirmed an “outperform” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a research note on Thursday, July 7th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of AVEO Pharmaceuticals in a research note on Thursday, June 16th. Finally, Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, May 31st.

AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.8699 on Wednesday. The stock has a 50 day moving average price of $0.94 and a 200-day moving average price of $0.96. The company’s market cap is $65.99 million. AVEO Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.47.

Several hedge funds have recently bought and sold shares of the company. New Leaf Venture Partners L.L.C. purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth approximately $2,490,000. Bridgeway Capital Management Inc. boosted its stake in shares of AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 200,000 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth approximately $281,000. Perceptive Advisors LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth approximately $2,987,000. Finally, Vanguard Group Inc. boosted its stake in shares of AVEO Pharmaceuticals by 1.1% in the second quarter. Vanguard Group Inc. now owns 2,470,485 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 27,304 shares in the last quarter. 39.10% of the stock is owned by hedge funds and other institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

5 Day Chart for NASDAQ:AVEO

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.